G0544

GR 103691

≥98% (HPLC), solid

• Sinónimos: 4′-Acetyl-N-[4-[4-(2-methoxyphenyl)-1-piperazinyl]butyl]-[1,1′-biphenyl]-4-carboxamide
• Fórmula empírica (notación de Hill): C₃₀H₃₅N₃O₃
• Número CAS: 162408-66-4
• Peso molecular: 485.62
• NACRES: NA.77
• PubChem Substance ID: 24724488
• UNSPSC Code: 12352200
• MDL number: MFCD00936840
• Assay: ≥98% (HPLC)
• Form: solid

Propiedades

• assay: ≥98% (HPLC)
• form: solid
• color: white
• solubility: DMSO: soluble >5 mg/mL at 60 °C
• originator: GlaxoSmithKline
• storage temp.: 2-8°C
• SMILES string: COc1ccccc1N2CCN(CCCCNC(=O)c3ccc(cc3)-c4ccc(cc4)C(C)=O)CC2
• InChI: 1S/C30H35N3O3/c1-23(34)24-9-11-25(12-10-24)26-13-15-27(16-14-26)30(35)31-17-5-6-18-32-19-21-33(22-20-32)28-7-3-4-8-29(28)36-2/h3-4,7-16H,5-6,17-22H2,1-2H3,(H,31,35)
• InChI key: JARNORYOPMINDY-UHFFFAOYSA-N
• Gene Information: rat ... Htr1a(24473)

Descripción

Application

GR 103691 has been used as a D3 receptor antagonist to test its:

• inducing effect on prepulse inhibition (PPI)[1]
• suppressive effect of motor behavior in rats[2]
• inhibitory effect on chemotaxis in newly excysted juvenile C. sinensis (CsNEJs)[3]

Biochem/physiol Actions

D₃ dopamine receptor antagonist.

GR 103691 increases the monosynaptic “stretch” reflex (MSR) amplitude in mice by its potent D3 receptor antagonist functionality.[4] It inhibits the PD 128,907 mediated γ-aminobutyric acid (GABA) release.[5]

Features and Benefits

This compound is featured on the Dopamine Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Legal Information

Sold for research purposes under agreement from Glaxo­Smith­Kline

Información de seguridad

• Clase de almacenamiento: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable
• ppe: Eyeshields, Gloves, type N95 (US)